Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Nov;70(11):7827–7832. doi: 10.1128/jvi.70.11.7827-7832.1996

Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.

J Weber 1, E M Fenyö 1, S Beddows 1, P Kaleebu 1, A Björndal 1
PMCID: PMC190853  PMID: 8892904

Abstract

Human immunodeficiency virus type 1 (HIV-1) primary isolates from four geographical locations in Thailand, Brazil, Rwanda, and Uganda, representing genetic subtypes A, B, C, D, and E, were examined for autologous and heterologous neutralization by panels of human HIV+ polyclonal plasma. In independent linked experiments in three laboratories using diverse methodologies and common reagents, no defined pattern of genetic subtype-specific neutralization was observed. Most plasma tested were broadly cross-neutralizing across two or more genetic subtypes, although the titer of neutralization varied across a wide range. We conclude that the genetic subtypes of HIV-1 are not classical neutralization serotypes.

Full Text

The Full Text of this article is available as a PDF (210.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nyström G., Fenyö E. M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS. 1990 Feb;4(2):107–112. doi: 10.1097/00002030-199002000-00002. [DOI] [PubMed] [Google Scholar]
  2. Albert J., Björling E., von Gegerfelt A., Scarlatti G., Zhang Y. J., Fenyö E. M., Thorstensson R. Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res Hum Retroviruses. 1993 Jun;9(6):501–504. doi: 10.1089/aid.1993.9.501. [DOI] [PubMed] [Google Scholar]
  3. Ariyoshi K., Harwood E., Chiengsong-Popov R., Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? Lancet. 1992 Nov 21;340(8830):1257–1258. doi: 10.1016/0140-6736(92)92953-d. [DOI] [PubMed] [Google Scholar]
  4. Cheingsong-Popov R., Lister S., Callow D., Kaleebu P., Beddows S., Weber J. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1379–1386. doi: 10.1089/aid.1994.10.1379. [DOI] [PubMed] [Google Scholar]
  5. D'Souza M. P., Milman G., Bradac J. A., McPhee D., Hanson C. V., Hendry R. M. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS. 1995 Aug;9(8):867–874. doi: 10.1097/00002030-199508000-00006. [DOI] [PubMed] [Google Scholar]
  6. Delwart E. L., Shpaer E. G., Louwagie J., McCutchan F. E., Grez M., Rübsamen-Waigmann H., Mullins J. I. Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science. 1993 Nov 19;262(5137):1257–1261. doi: 10.1126/science.8235655. [DOI] [PubMed] [Google Scholar]
  7. Fiscus S. A., DeGruttola V., Gupta P., Katzenstein D. A., Meyer W. A., 3rd, LoFaro M. L., Katzman M., Ragni M. V., Reichelderfer P. S., Coombs R. W. Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis. 1995 Feb;171(2):305–311. doi: 10.1093/infdis/171.2.305. [DOI] [PubMed] [Google Scholar]
  8. Gao F., Yue L., Craig S., Thornton C. L., Robertson D. L., McCutchan F. E., Bradac J. A., Sharp P. M., Hahn B. H. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1359–1368. doi: 10.1089/aid.1994.10.1359. [DOI] [PubMed] [Google Scholar]
  9. Kostrikis L. G., Cao Y., Ngai H., Moore J. P., Ho D. D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol. 1996 Jan;70(1):445–458. doi: 10.1128/jvi.70.1.445-458.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Louwagie J., McCutchan F. E., Peeters M., Brennan T. P., Sanders-Buell E., Eddy G. A., van der Groen G., Fransen K., Gershy-Damet G. M., Deleys R. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 1993 Jun;7(6):769–780. doi: 10.1097/00002030-199306000-00003. [DOI] [PubMed] [Google Scholar]
  11. Mascola J. R., Louwagie J., McCutchan F. E., Fischer C. L., Hegerich P. A., Wagner K. F., Fowler A. K., McNeil J. G., Burke D. S. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis. 1994 Jan;169(1):48–54. doi: 10.1093/infdis/169.1.48. [DOI] [PubMed] [Google Scholar]
  12. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996 Jan;70(1):427–444. doi: 10.1128/jvi.70.1.427-444.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ou C. Y., Takebe Y., Weniger B. G., Luo C. C., Kalish M. L., Auwanit W., Yamazaki S., Gayle H. D., Young N. L., Schochetman G. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet. 1993 May 8;341(8854):1171–1174. doi: 10.1016/0140-6736(93)91001-3. [DOI] [PubMed] [Google Scholar]
  14. Sawyer L. S., Wrin M. T., Crawford-Miksza L., Potts B., Wu Y., Weber P. A., Alfonso R. D., Hanson C. V. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol. 1994 Mar;68(3):1342–1349. doi: 10.1128/jvi.68.3.1342-1349.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Spouge J. L. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7581–7585. doi: 10.1073/pnas.89.16.7581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sundqvist V. A., Albert J., Ohlsson E., Hinkula J., Fenyö E. M., Wahren B. Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol. 1989 Nov;29(3):170–175. doi: 10.1002/jmv.1890290305. [DOI] [PubMed] [Google Scholar]
  17. Weber J., Cheinsong-Popov R., Callow D., Adams S., Patou G., Hodgkin K., Martin S., Gotch F., Kingsman A. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine. 1995 Jun;13(9):831–834. doi: 10.1016/0264-410x(94)00061-q. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES